Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease

A new oral vaccine for Alzheimer's disease was developed using recombinant adeno-associated virus vector carrying Aβ cDNA (AAV/Aβ). Oral administration of the vaccine without adjuvant induced the expression and secretion of Aβ1-43 or Aβ1-21 in the epithelial cell layer of the intestine in amyloid precursor protein transgenic mice. Serum antibody levels were elevated for more than six months, while T cell proliferative responses to Aβ was not detected. Brain Aβ burden was significantly decreased compared to the control without inflammatory changes. This oral AAV/A β vaccine seems to be promising for prevention and treatment of Alzheimer's disease.